It is with interest that we read the results of the Eisen et al 1 study comparing oral valacyclovir to acyclovir for the prevention of herpes simplex virus (HSV) mucositis following high-dose chemotherapy (CT) with autologous stem cell transplantation (AuSCT). Indeed, there are now three published studies comparing these drugs.
1-3 Although these trials all indicate that valacyclovir is equivalent in efficacy, the trials differ in patient population examined, design (historical comparisons vs randomised), dose administered and end point measurement, and thus it remains unclear what dose and schedule of valacyclovir is appropriate.
At our hospital, we have also evaluated the incidence of breakthrough HSV infection in 98 patients treated with a lower dose of oral valacyclovir, 500 mg daily. Table 1 .
Given the information available to date, it seems appropriate to consider valacyclovir as an alternative to acyclovir but given the inherent difficulties of comparing trials, particularly those that include historical controls, only a prospective randomised trial will answer the question of the appropriate dose and schedule of valacyclovir. Indeed, published evidence indicates that not only total dose but also schedule may be important. 
